FONDAPARINUX SODIUM (fon-da-par'i-nux) Arixtra Classifications: blood formers, coagulators & anticoagulants; anticoagulant; low-molecular weight heparin Prototype: Enoxaparin Pregnancy Category: B |
2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, 10 mg/0.8 mL syringe
Fondaparinux sodium causes antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. Fondaparinux selectively binds to ATIII, potentiating the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa by fondaparinux interrupts the blood coagulation cascade, inhibiting thrombin formation and, thus, thrombus development. Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function, therefore, it rarely causes thrombocytopenia.
Fondaparinux is effective in the prevention and treatment of deep-vein thrombosis. The laboratory value utilized to determine the effectiveness of the drug is the amount of anti-Xa assay expressed in mg.
Prophylaxis for DVT or pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery or abdominal surgery; treatment of acute DVT without PE with warfarin, treatment of PE with warfarin.
Hypersensitivity to fondaparinux; active bleeding; GI bleeding; severe renal impairment with a creatinine clearance of <30 mL/min; weight <50 kg; active major bleeding; bacterial endocarditis; intramuscular administration; thrombocytopenia associated with fondaparinux. Safety and effectiveness in children have not been established.
Renal impairment or disease; older adult; indwelling epidural catheter; dental disease, dental work; diabetic retinopathy; diverticulitis; endocarditis, epidural anesthesia; hemophilia, heparin-induced thrombocytopenia (HIT), hepatic disease, hypertension, idiopathic thrombocytopenia purpura (ITP); inflammatory bowel disease, lumbar puncture, spinal anesthesia; stroke, surgery; thrombocytopenia, thrombolytic therapy; vaginal bleeding, menstruation; peptic ulcer disease; pregnancy (category B); bleeding disorders including a history of GI ulceration, etc., history of heparininduced thrombocytopenia; lactation.
DVT, Pulmonary Embolism Prophylaxis Adult: SC >50 kg 2.5 mg q.d. starting at least 6 h postsurgery times 59 days; for hip fracture patients, up to 24 d additional use Treatment of DVT, Pulmonary Embolism Adult: SC <50 kg, 5 mg; 50100 kg, 7.5 mg; >100 kg, 10 mg once daily x 59 d Renal Impairment Clcr 3050 mL/min, use with caution; <30 mL/min, use is contraindicated |
Assessment & Drug Effects
Patient & Family Education